Tau positron emission tomographic imaging in aging and early Alzheimer disease

Keith A. Johnson, Aaron Schultz, Rebecca Betensky, J. Alex Becker, Jorge Sepulcre, Dorene Rentz, Elizabeth Mormino, Jasmeer Chhatwal, Rebecca Amariglio, Kate Papp, Gad Marshall, Mark Albers, Samantha Mauro, Lesley Pepin, Jonathan Alverio, Kelly Judge, Marlie Philiossaint, Timothy Shoup, Daniel Yokell, Bradford DickersonTeresa Gomez-Isla, Bradley Hyman, Neil Vasdev, Reisa Sperling

Research output: Contribution to journalArticle

Abstract

Objective Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease-modifying therapies. Methods We acquired tau positron emission tomography (PET) using 18F T807 (AV1451), and amyloid-β PET using 11C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia. Results We found abnormally high cortical 18F T807 binding in patients with mild cognitive impairment and AD dementia compared to clinically normal controls. Consistent with the neuropathology literature, the presence of elevated neocortical 18F T807 binding particularly in the inferior temporal gyrus was associated with clinical impairment. The association of cognitive impairment was stronger with inferior temporal 18F T807 than with mean cortical 11C PIB. Regional 18F T807 was correlated with mean cortical 11C PiB among both impaired and control subjects. Interpretation These findings suggest that 18F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment.

Original languageEnglish (US)
Pages (from-to)110-119
Number of pages10
JournalAnnals of Neurology
Volume79
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Alzheimer Disease
Electrons
Positron-Emission Tomography
Tauopathies
Temporal Lobe
Amyloid
Disease Progression
Biomarkers
Brain
Cognitive Dysfunction
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Johnson, K. A., Schultz, A., Betensky, R., Becker, J. A., Sepulcre, J., Rentz, D., ... Sperling, R. (2016). Tau positron emission tomographic imaging in aging and early Alzheimer disease. Annals of Neurology, 79(1), 110-119. https://doi.org/10.1002/ana.24546

Tau positron emission tomographic imaging in aging and early Alzheimer disease. / Johnson, Keith A.; Schultz, Aaron; Betensky, Rebecca; Becker, J. Alex; Sepulcre, Jorge; Rentz, Dorene; Mormino, Elizabeth; Chhatwal, Jasmeer; Amariglio, Rebecca; Papp, Kate; Marshall, Gad; Albers, Mark; Mauro, Samantha; Pepin, Lesley; Alverio, Jonathan; Judge, Kelly; Philiossaint, Marlie; Shoup, Timothy; Yokell, Daniel; Dickerson, Bradford; Gomez-Isla, Teresa; Hyman, Bradley; Vasdev, Neil; Sperling, Reisa.

In: Annals of Neurology, Vol. 79, No. 1, 01.01.2016, p. 110-119.

Research output: Contribution to journalArticle

Johnson, KA, Schultz, A, Betensky, R, Becker, JA, Sepulcre, J, Rentz, D, Mormino, E, Chhatwal, J, Amariglio, R, Papp, K, Marshall, G, Albers, M, Mauro, S, Pepin, L, Alverio, J, Judge, K, Philiossaint, M, Shoup, T, Yokell, D, Dickerson, B, Gomez-Isla, T, Hyman, B, Vasdev, N & Sperling, R 2016, 'Tau positron emission tomographic imaging in aging and early Alzheimer disease', Annals of Neurology, vol. 79, no. 1, pp. 110-119. https://doi.org/10.1002/ana.24546
Johnson, Keith A. ; Schultz, Aaron ; Betensky, Rebecca ; Becker, J. Alex ; Sepulcre, Jorge ; Rentz, Dorene ; Mormino, Elizabeth ; Chhatwal, Jasmeer ; Amariglio, Rebecca ; Papp, Kate ; Marshall, Gad ; Albers, Mark ; Mauro, Samantha ; Pepin, Lesley ; Alverio, Jonathan ; Judge, Kelly ; Philiossaint, Marlie ; Shoup, Timothy ; Yokell, Daniel ; Dickerson, Bradford ; Gomez-Isla, Teresa ; Hyman, Bradley ; Vasdev, Neil ; Sperling, Reisa. / Tau positron emission tomographic imaging in aging and early Alzheimer disease. In: Annals of Neurology. 2016 ; Vol. 79, No. 1. pp. 110-119.
@article{f555e14777114859b3d0bff03c4603e3,
title = "Tau positron emission tomographic imaging in aging and early Alzheimer disease",
abstract = "Objective Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease-modifying therapies. Methods We acquired tau positron emission tomography (PET) using 18F T807 (AV1451), and amyloid-β PET using 11C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia. Results We found abnormally high cortical 18F T807 binding in patients with mild cognitive impairment and AD dementia compared to clinically normal controls. Consistent with the neuropathology literature, the presence of elevated neocortical 18F T807 binding particularly in the inferior temporal gyrus was associated with clinical impairment. The association of cognitive impairment was stronger with inferior temporal 18F T807 than with mean cortical 11C PIB. Regional 18F T807 was correlated with mean cortical 11C PiB among both impaired and control subjects. Interpretation These findings suggest that 18F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment.",
author = "Johnson, {Keith A.} and Aaron Schultz and Rebecca Betensky and Becker, {J. Alex} and Jorge Sepulcre and Dorene Rentz and Elizabeth Mormino and Jasmeer Chhatwal and Rebecca Amariglio and Kate Papp and Gad Marshall and Mark Albers and Samantha Mauro and Lesley Pepin and Jonathan Alverio and Kelly Judge and Marlie Philiossaint and Timothy Shoup and Daniel Yokell and Bradford Dickerson and Teresa Gomez-Isla and Bradley Hyman and Neil Vasdev and Reisa Sperling",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/ana.24546",
language = "English (US)",
volume = "79",
pages = "110--119",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Tau positron emission tomographic imaging in aging and early Alzheimer disease

AU - Johnson, Keith A.

AU - Schultz, Aaron

AU - Betensky, Rebecca

AU - Becker, J. Alex

AU - Sepulcre, Jorge

AU - Rentz, Dorene

AU - Mormino, Elizabeth

AU - Chhatwal, Jasmeer

AU - Amariglio, Rebecca

AU - Papp, Kate

AU - Marshall, Gad

AU - Albers, Mark

AU - Mauro, Samantha

AU - Pepin, Lesley

AU - Alverio, Jonathan

AU - Judge, Kelly

AU - Philiossaint, Marlie

AU - Shoup, Timothy

AU - Yokell, Daniel

AU - Dickerson, Bradford

AU - Gomez-Isla, Teresa

AU - Hyman, Bradley

AU - Vasdev, Neil

AU - Sperling, Reisa

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease-modifying therapies. Methods We acquired tau positron emission tomography (PET) using 18F T807 (AV1451), and amyloid-β PET using 11C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia. Results We found abnormally high cortical 18F T807 binding in patients with mild cognitive impairment and AD dementia compared to clinically normal controls. Consistent with the neuropathology literature, the presence of elevated neocortical 18F T807 binding particularly in the inferior temporal gyrus was associated with clinical impairment. The association of cognitive impairment was stronger with inferior temporal 18F T807 than with mean cortical 11C PIB. Regional 18F T807 was correlated with mean cortical 11C PiB among both impaired and control subjects. Interpretation These findings suggest that 18F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment.

AB - Objective Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease-modifying therapies. Methods We acquired tau positron emission tomography (PET) using 18F T807 (AV1451), and amyloid-β PET using 11C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia. Results We found abnormally high cortical 18F T807 binding in patients with mild cognitive impairment and AD dementia compared to clinically normal controls. Consistent with the neuropathology literature, the presence of elevated neocortical 18F T807 binding particularly in the inferior temporal gyrus was associated with clinical impairment. The association of cognitive impairment was stronger with inferior temporal 18F T807 than with mean cortical 11C PIB. Regional 18F T807 was correlated with mean cortical 11C PiB among both impaired and control subjects. Interpretation These findings suggest that 18F T807 PET could have value as a biomarker that reflects both the progression of AD tauopathy and the emergence of clinical impairment.

UR - http://www.scopus.com/inward/record.url?scp=84956583549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956583549&partnerID=8YFLogxK

U2 - 10.1002/ana.24546

DO - 10.1002/ana.24546

M3 - Article

VL - 79

SP - 110

EP - 119

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -